Abaloparatide 3 mg vial dosage

What Abaloparatide is

Class:

Synthetic parathyroid hormone-related protein (PTHrP) analogue, a peptide

Also called:

Tymlos

Used for:

FDA-approved to treat osteoporosis in postmenopausal women at high fracture risk, and to increase bone density in men with osteoporosis at high fracture risk, by stimulating new bone formation.

Human evidence:

Strong human evidence. FDA approval rests on the ACTIVE trial, a randomised, placebo- and active-comparator-controlled study in postmenopausal women with osteoporosis, which found abaloparatide reduced new vertebral fractures and increased bone mineral density versus placebo. The adverse-reaction rates on the approved label come from that trial data.

US status:

FDA-approved · prescription only. FDA-approved as Tymlos since 2017 for postmenopausal women, with the label later expanded to include men; requires a prescription. I could not verify a Therapeutic Goods Administration approval or ARTG listing for abaloparatide, so Australian status is not stated as approved.

The full picture, with every study: Abaloparatide guide.

How to mix a 3 mg Abaloparatide vial

For this vial: 2 mL of bacteriostatic water makes 1.5 mg/mL, so 80 mcg is 5.5 units (0.05 mL) on a U-100 insulin syringe. Pick a different volume from the units table if you want bigger or smaller draws; the number of doses stays the same.

1. Wipe the rubber stoppers of both the peptide vial and the bacteriostatic water vial with an alcohol swab and let the alcohol dry. ^[2][3]
2. With a new sterile needle and syringe, draw up the amount of bacteriostatic water you have chosen for the dilution. ^[2][3][4]
3. Inject the water into the peptide vial by aiming the stream against the inside glass wall, which helps prevent foaming. ^[5]
4. Swirl or roll the vial gently until the powder has fully dissolved; do not shake it. Do not inject the solution if it is cloudy or has particles in it. ^[2][3][5]
5. Label the vial with the date and time it was mixed, the amount of water added and how long it can be used after mixing. ^[2]
6. Store the mixed vial in the refrigerator at 2-8°C (36-46°F) and do not freeze it. ^[5]

Step by step with pictures: how to reconstitute peptides. About the water itself: bacteriostatic water.

Storing Abaloparatide vials

• Freeze-dried (lyophilized) peptide keeps far longer than peptide in solution; peptide suppliers advise storing the powder at -20°C away from bright light. ^[6]
• Protect peptide vials from heat and light. ^[6][7]
• Avoid repeated freeze-thaw cycles; a prescription peptide label also says not to freeze a vial once it has been mixed. ^[5][6]
• Once a multi-dose vial, such as bacteriostatic water, has been opened (needle-punctured), date it and discard it within 28 days unless its manufacturer states another date. ^[8][9]

More detail: peptide storage and shelf life.

Injecting safely

• Clean the injection site with an alcohol swab and let the skin dry completely before injecting. ^[10][11]
• Pinch up a fold of skin and fat (not muscle) and insert the needle at a 45- to 90-degree angle: 90 degrees where there is enough fatty tissue, 45 degrees where there is little. ^[10][11][12]
• Pulling back on the plunger (aspiration) is not necessary for a subcutaneous injection, because the chance of the needle being in a blood vessel is small. ^[10]
• Inject slowly, at roughly 10 seconds per mL. ^[10]
• Common sites are the belly, the thigh and the upper arm; rotate sites, keeping each injection at least 1 inch (2.5 cm) from the last. ^[5][10][11]

Hygiene and warning signs

• Use a new sterile needle and syringe for every injection and every time you enter a vial; never reuse them. ^[4][8][11]
• Never share needles, syringes or pens with anyone, even if the needle is changed; unsafe injection practices spread hepatitis B, hepatitis C and HIV. ^[4][7][8]
• Put used needles and syringes in a sharps disposal container straight away (FDA-cleared if possible), never loose in the trash, recycling or toilet, and dispose of the container following your community's guidelines. ^[13][14]
• Contact a health care provider if the injection site shows signs of infection, such as redness, swelling, red streaks or a fever. ^[11]

Where to inject: subcutaneous injection sites.

How Abaloparatide works

• Abaloparatide is a synthetic 34-amino-acid peptide modelled on human parathyroid hormone-related peptide, PTHrP(1-34). Its sequence shares 76% with PTHrP(1-34) and 41% with parathyroid hormone (1-34), the basis of teriparatide. ^[1]
• It activates the PTH1 receptor, switching on cAMP signalling in target cells. Given once a day, it builds new bone on inner (trabecular) and outer (cortical) bone surfaces by stimulating bone-forming osteoblasts. ^[1]
• In cell studies, abaloparatide bound one conformation of the PTH1 receptor (RG) more selectively than PTH(1-34) did, giving shorter cAMP signals. The authors offer this as a plausible explanation for its bone-building effect, noting that animal studies had suggested less bone resorption and less rise in blood calcium than with PTH(1-34). ^[15]

What the Abaloparatide research found

Human evidence: strong human evidence. Each result says what was studied.

• Human studyIn the 18-month ACTIVE trial in postmenopausal women with osteoporosis (824 on abaloparatide, 821 on placebo), new vertebral fractures occurred in 0.6% on abaloparatide against 4.2% on placebo, a relative reduction of 86%. ^[1][16]
• FDA labelIn the same trial, non-vertebral fractures occurred in 2.7% on abaloparatide against 4.7% on placebo, a relative reduction of 43%. ^[1]
• FDA labelWhen women from ACTIVE then took alendronate for 6 months, new vertebral fractures by 25 months were 0.6% in the former abaloparatide group against 4.4% in the former placebo group. ^[1]
• Human studyACTIVE also included an open-label teriparatide group. High blood calcium was less common on abaloparatide than on teriparatide (3.4% vs 6.4%). ^[16]
• FDA labelIn a 12-month placebo-controlled trial of 228 men with osteoporosis, lumbar spine bone density rose 8.5% on abaloparatide against 1.2% on placebo. ^[1]

Abaloparatide side effects and risks

• FDA labelIn postmenopausal women, the most common adverse reactions (2% or more) were hypercalciuria (high urine calcium), dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain and vertigo. In men, the most common included injection-site redness, swelling and pain, dizziness, joint pain, bruising, nausea, diarrhoea, abdominal pain and bone pain. ^[1]
• Animal studyIn rats, abaloparatide caused a dose-dependent rise in osteosarcoma (a bone cancer) at 4 to 28 times human exposure. Whether it causes osteosarcoma in humans is unknown, and the label says to avoid it in people at higher baseline risk. ^[1]
• FDA labelOrthostatic hypotension (a blood-pressure drop on standing) can occur, usually within 4 hours of a dose, with dizziness, palpitations, fast heart rate or nausea. Heart rate rises within 15 minutes of injection, more so at higher doses, and settles in about 6 hours. ^[1]
• FDA labelIn the women's trial, high blood calcium 4 hours after a dose occurred in 3% on abaloparatide against 0.1% on placebo. Kidney stones were reported in 2.1% against 1.7%. ^[1]
• FDA labelIn the first month of the women's trial, injection-site redness (58% vs 28%), swelling (11% vs 3%) and pain (10% vs 7%) were more common than on placebo. Overall, 10% stopped abaloparatide because of adverse events, against 6% on placebo. ^[1]

Other things to know

• Label carries osteosarcoma warnings-section language after abaloparatide caused a dose-dependent increase in osteosarcoma in male and female rats; the label advises against use in patients at increased baseline osteosarcoma risk (open epiphyses, metabolic bone diseases, bone metastases or skeletal malignancies, prior skeletal radiation, hereditary disorders predisposing to osteosarcoma).
• The label states safety and efficacy have not been evaluated beyond 2 years of treatment, and use for more than 2 years during a patient's lifetime is not recommended.
• Transient hypercalcemia and orthostatic hypotension can occur shortly after injection; the label advises administering the first several doses where the patient can sit or lie down.
• Sold to consumers as an unlabelled "research" vial outside the approved Tymlos supply chain carries none of this label's dosing, quality control or prescriber oversight.

Reported side effects and what the studies measured: Abaloparatide side effects.

Where this vial size comes from

Abaloparatide is sold as a 3 mg vial by the page below, each checked on the date shown. I list them as evidence that this size exists, not as a recommendation to buy from them.

• DailyMed (TYMLOS label)labelLists it as: Each cartridge contains 1.56 mL solution with 3.12 mg of abaloparatide (2000 mcg/mL) · checked 2026-09-28

The doses come from the FDA label on the Abaloparatide dosing page, and every number on this page is arithmetic on those doses and this vial size.

Questions

How much water do I add to a 3 mg Abaloparatide vial?

There is no single correct amount: water changes how many units a dose is, not how many doses the vial holds. With 2 mL the vial is 1.5 mg/mL and 80 mcg is 5.5 units (0.05 mL) on a U-100 insulin syringe. The units table gives 2, 3, 5 mL.

How many doses are in a 3 mg Abaloparatide vial?

37 doses at 80 mcg.

What does 1 unit equal in a 3 mg Abaloparatide vial?

15 mcg with 2 mL, 10 mcg with 3 mL, 6 mcg with 5 mL of bacteriostatic water, on a U-100 syringe.